Document is current

Article History

Accepted: 31 July 2024

First Online: 4 September 2024

Competing interests

: C.K.C. reports receiving consulting and speaker fees from Alexion, Alpine Immune Sciences, Calliditas, Chinook, CSL Vifor, George Clinical, Novartis, Otsuka, Stada, Travere Therapeutics, Vera Therapeutics; receiving grant support from Travere Therapeutics; and being on data-monitoring committees for Roche and Alpine Immune Sciences. H.N.R. has provided consultation for Calliditas, Chinook, Novartis and Omeros, and provided a conference lecture supported by Travere Therapeutics; serves on the steering committee of IgA studies for Calliditas and Chinook (a Novartis company); has attended advisory meetings for Otsuka, Pfizer and Eledon; is a clinical trial site investigator for Calliditas, Omeros and Alnylam; and directs the Louise Fast Foundation fellowship. H.Z. is employed by Peking University First Hospital and reports receiving consultancy fees for being a Steering Committee member from Novartis, Omeros, Calliditas, Chinook and Otsuka; and having participated in symposia or panel discussions and received honoraria for scientific presentations from Omeros and Novartis. J.B. reports consultancy for Alebund, Alnylam, Alpine, Argenx, Astellas, BioCryst, Calliditas, Chinook, Dimerix, HiBio, Kira, Novartis, Omeros, Otsuka, Q32 Bio, Roche, Sanofi, Takeda, Travere Therapeutics, Vera Therapeutics, Vifor and Visterra; research funding from Argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Travere Therapeutics and Visterra; a role on the Editorial Boards of <i>CJASN</i>, <i>Clinical Science</i>, <i>Glomerular Diseases</i> and <i>Kidney International</i>; and an advisory or leadership role as Treasurer of the International IgA Nephropathy Network. The other authors declare no competing interests.